VTP 201227

Drug Profile

VTP 201227

Alternative Names: VTP-201227

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Vitae Pharmaceuticals
  • Class Antipsoriatics; Skin disorder therapies
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne; Psoriasis

Most Recent Events

  • 11 Jan 2011 Discontinued - Phase-II for Psoriasis in USA (Topical)
  • 11 Jan 2011 Discontinued - Preclinical for Acne in USA (Topical)
  • 29 Nov 2005 Phase-II clinical trials in Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top